



Qty: 100 µg/200 µL

Mouse anti-nNOS

Catalog No. 37-2800

Lot No.

Mouse anti-nNOS

FORM

This monoclonal antibody is supplied as a 200 µL aliquot at a concentration of 0.5 mg/mL in PBS, pH 7.4, containing 0.1% sodium azide. This antibody is highly purified from mouse ascites by protein-A chromatography.

CLONE: 3G6B10

ISOTYPE: IgG₁-kappa

IMMUNOGEN

Recombinant protein derived from the N-terminal region of rat nNOS protein.

SPECIFICITY

This antibody is specific for the ~160 kDa nNOS.

REACTIVITY

Reactivity has been confirmed with rat brain tissue lysates. The nNOS target band at ~160 kDa was detected by immunoprecipitation and Western blots. Immunohistochemical tests using human, mouse, and rat brain tissue sections yielded positive and specific cytoplasmic staining in neurons and astrocytes. Based on amino acid sequence homology, the antibody is expected to recognize mouse (95%) and human (81%) nNOS.

Sample	Immuno-precipitation ¹	Western Blotting	Immunohistochemistry (FFPE)	ELISA
Rat	+++	+++	+++	N/A
Mouse	ND	ND	+++	N/A
Human	ND	ND	+++	N/A
Immunogen	N/A	N/A	N/A	+++

(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Western Blotting: 1 µg/mL

ELISA: 0.1-1.0 µg/mL

Immunoprecipitation: 7 µg/each

Immunohistochemistry (FFPE): 2 µg/mL

STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long-term storage. Avoid repeated freezing and thawing.

BACKGROUND

Nitric oxide (NO) is a potent bio-regulatory molecule which plays important roles in the regulation of a variety of normal developmental and physiological processes¹⁻³. NO is generated by nitric oxide synthase (NOS) in a reaction which converts L-arginine and oxygen into citrulline and nitric oxide¹⁻³. Three distinct mammalian genes have been identified which encode NOS isoforms: neuronal (nNOS or bNOS), macrophage or inducible (iNOS), and endothelial (eNOS)¹⁻⁴. The NOS isoforms can be subdivided into two general categories, constitutive or inducible, based on differences in their regulation and activities¹. The constitutive isoforms include eNOS and nNOS¹⁻³. Although the nomenclature of the NOS family members suggests restricted isoform expression patterns, the 160 kDa neuronal-type NO synthase (nNOS) has been detected in a variety of cell types including neurons, epithelial cells, mesangial cells, and skeletal muscle cells.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI372800

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

nNOS is a widely distributed calmodulin-regulated enzyme whose activity is coupled to several neurotransmitter systems both in the brain and in peripheral tissues. The physiological role of nNOS has been perhaps best characterized in the peripheral nervous system, where NO functions as a nonadrenergic-noncholinergic transmitter in several pathways in the gastrointestinal and urogenital tracts. In the CNS, deregulation of nNOS in the brain is associated with over activation of the glutamate receptor and appears to contribute to neuronal damage in animal models of stroke⁵. Mice that lack nNOS are more resistant to neuronal damage following focal cerebral ischemia⁶. Unlike eNOS, the nNOS protein lacks a consensus sequence for fatty acid modification. Nevertheless, nNOS is localized primarily to the particulate fraction via its interactions with specific membrane proteins⁷. In skeletal muscle, nNOS is enriched in fast-twitch muscle fibers where it associates with the sarcolemma⁸. This association with skeletal muscle membranes is due to the association of nNOS with dystrophin⁹. In particular, the dystrophin complex interacts with the N-terminus of nNOS which contains a GLGF motif present in other cytoskeletal-associated proteins⁹. In cases where dystrophin is absent such as in human Duchenne muscular dystrophy (DMD) or *mdx* mice, nNOS can no longer be detected in the sarcolemma and accumulates in the cytosol. This aberrant targeting of nNOS is thought to play a role in the preferential degeneration of fast-twitch muscle fibers seen in DMD⁹. The GLGF motif is also thought to be involved in anchoring nNOS to synaptic membranes complexes in the brain¹⁰.

REFERENCES

1. Sessa WC. *J Vasc Res* 31:131-143, 1994.
2. Lowenstein CL *et al. Annals of Int Med* 120:227-237, 1994.
3. Nathan C *et al. J Biol Chem* 269:13725-13728, 1994.
4. Snyder S. *Nature* 377:196-197, 1995.
5. Dawson TM *et al. Ann Neurol* 32:297-311, 1992.
6. Huang PL *et al. Science* 265:1883-1885, 1994.
7. Hecker M *et al. J Neurochem* 62:1524-1529, 1994
8. Kobzik L *et al. Nature* 372:546-548, 1994.
9. Brenman JE *et al. Cell* 82:743-752, 1995.
10. Bredt DS. *Proc Soc Exp Biol Med* 211:41-48, 1996.

RELATED PRODUCTS

Product	PAD*clone	Cat. No.
Ms x Nitrotyrosine	HM11	32-2900
Ms x eNOS	eNOS-6C6	33-4500
Ms x eNOS	eNOS-9D10	33-4600
Rb x phospho-eNOS (Ser1179)	ZMD.279	36-9100
Rb x iNOS	Z-JL8	61-7700
Rb x nNOS	Z-RNN3	61-7000
Ms x Calmodulin	CaM85	13-6900
Rb x Calmodulin	-	61-8500
Ms x α -CaM Kinase II	CB α -2	13-7300
Ms x β -CaM Kinase II	CB β -2	13-9800
Rb x phospho-CaM Kinase II (Thr286)	PS286	36-9100

Protein A	Sepharose [®] 4B	10-1041
rec-Protein G	Sepharose [®] 4B	10-1241

*PAD: Polyclonal Antibody Designation

Conjugate	ZyMAX™ Goat x Rabbit IgG (H+L)	ZyMAX™ Goat x Mouse IgG (H+L)
Purified	81-6100	81-6500
FITC	81-6111	81-6511
TRITC	81-6114	81-6514
Cy™3	81-6115	81-6515
Cy™5	81-6116	81-6516
HRP	81-6120	81-6520
AP	81-6122	81-6522
Biotin	81-6140	81-6540

ZyMed[®] and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ and Sepharose[®] are registered trademarks of Amersham Biosciences Ltd.

For Research Use Only

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI372800

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.